I see a cup and handle forecast called out here, which is a possibility with the way the current COVID market is moving. HTBX does have a few bright spots in early faces of trials, one of which for tumor destruction: "PTX-35 is a novel, first-in-class agonist antibody targeting TNFRSF25, also known as death receptor 3 (DR3), a receptor that is preferentially...
HTBX has broken the long term downward trendlines with a huge increase in volume. I'm expecting more upside. Possible target on chart.
Oh., how great... management bought some stock at $0.75 and they took back a public offering. The stock climbed and has momentum, but why? The company is still producing revenues of $0 and ops are getting more expensive. Earnings keep getting more negative, don't expect anything good to come out of their reporting coming up in August. Short at ~1.15 this morning...
$HTBX Watch for .74 breakout. Director bought 1M shares at .75.